drugset / Trial / NCT00242489
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of etoricoxib in the treatment of osteoarthritis of the knee.
Timeline
- Start
- 1998-06
- Primary completion
- 1999-02
- Completion
- 2002-07
Outcome
Met primary endpoint
paper Compared with placebo, the etoricoxib groups displayed significant (p < 0.05), dose-dependent efficacy for all primary endpoints in Part I; PMID 16321158 ↗
Publications
- Background Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ; Protocol 007 Study Group. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford). 2002 Sep;41(9):1052-61. doi: 10.1093/rheumatology/41.9.1052.
- Results Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, Reicin AS. Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005 Dec 1;6:58. doi: 10.1186/1471-2474-6-58.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diclofenac | Other / unclassified | 50 mg | — |
| Subject | Etoricoxib | Small molecule | 5 mg | Oral |
| Subject | Etoricoxib | Small molecule | 10 mg | Oral |
| Subject | Etoricoxib | Small molecule | 30 mg | Oral |
| Subject | Etoricoxib | Small molecule | 60 mg | Oral |
| Subject | Etoricoxib | Small molecule | 90 mg | Oral |